PR Newswire Clinical TrialsOriginal article
CureGene Completes First‑Participant Dose in Phase I Trial of CG‑0416, Advancing Clinical Development of Novel Oral Liver-Targeting THR-β Agonist
Phase 1CG-0416Positive
AI Analysis
Summary
CureGene announced the first participant dose in its Phase I clinical trial of CG-0416, a novel oral liver-targeting THR-β agonist, with enrollment progressing smoothly in Australia.
Clinical Trial Data
Phase
Phase I
Patients
1
Outcome Details
First participant dosed in Phase I trial
Importance:5/10
Sentiment:
0.60
Phase 1oral drugliver-targetingTHR-beta agonistAustraliatrial initiation
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on August 21, 2026 12:08 PM